Tropichem has unveiled plans for the expansion of its North American manufacturing capabilities, adding a non-sterile liquid facility for production of anti-parasiticide spot-ons and other registered product categories. Tropichem is a contract development and manufacturing organization (CDMO) that specializes in complex drug product formulation and manufacturing of veterinary pharmaceutical products.
 
The company’s Montreal, Canada location was chosen based on the company’s March 2018 acquisition of Tetragenx, leveraging the existing validation batch scale manufacturing for product development and technical transfers.

“When we acquired Tetragenx six months ago, we created a CDMO and outlined a manufacturing strategy to address unmet needs in the animal health industry,” said John Kane, chief executive officer, Tropichem. “This investment is our first step toward our goal of becoming the industry’s leading CDMO.” 
 
Commercial production will commence in January 2019, and additional investments for other dosage forms will be announced later this year.